Trials / Completed
CompletedNCT03878433
Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to decrease melasma severity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glisodin | 500 mg/day between 12 weeks |
| OTHER | placebo | Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2020-01-01
- Completion
- 2020-07-01
- First posted
- 2019-03-18
- Last updated
- 2021-09-14
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03878433. Inclusion in this directory is not an endorsement.